Clinical Trials

GlaxoSmithKline has sponsored numerous clinical trials evaluating GSK2982772, all of which are completed. Spanning Phase I and Phase II, these evaluations investigated the compound's safety, tolerability, pharmacokinetics, and preliminary efficacy in human subjects. Specific indications studied include rheumatoid arthritis, ulcerative colitis, psoriasis, and general inflammatory bowel diseases for therapeutic application in chronic autoimmune conditions.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04316585 COMPLETED
Psoriasis
GlaxoSmithKline
 2020-09-28 PHASE1
NCT02903966 COMPLETED
Colitis, Ulcerative
GlaxoSmithKline
 2016-11-15 PHASE2
NCT03649412 COMPLETED
Autoimmune Diseases
GlaxoSmithKline
 2018-09-26 PHASE1
NCT03266172 COMPLETED
Autoimmune Diseases
GlaxoSmithKline
 2017-09-27 PHASE1
NCT02858492 COMPLETED
Arthritis, Rheumatoid
GlaxoSmithKline
 2016-10-17 PHASE2
NCT03305419 COMPLETED
Autoimmune Diseases
GlaxoSmithKline
 2017-10-11 PHASE1
NCT03590613 COMPLETED
Autoimmune Diseases
GlaxoSmithKline
 2018-07-19 PHASE1
NCT03590613 Completed
Autoimmune Diseases
GlaxoSmithKline
 2018-07-19 Phase 1
NCT02776033 COMPLETED
Psoriasis
GlaxoSmithKline
 2016-08-30 PHASE2
NCT03305419 Completed
Autoimmune Diseases
GlaxoSmithKline
 2017-10-11 Phase 1
NCT02903966 Completed
Colitis Ulcerative
GlaxoSmithKline
 2016-11-15 Phase 2
NCT02858492 Completed
Arthritis Rheumatoid
GlaxoSmithKline
 2016-10-17 Phase 2
NCT02302404 COMPLETED
Inflammatory Bowel Diseases
GlaxoSmithKline
 2015-01-06 PHASE1

(data from https://clinicaltrials.gov, updated on 2024-03-18)

Check the GSK2982772 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

GSK2982772 is an ATP-competitive receptor-interacting protein-1 (RIP1) kinase inhibitor with an IC50 of 16 nM that potently suppresses downstream pro-inflammatory signaling cascades and TNF-dependent cellular responses. By selectively blocking RIP1 kinase activity, the compound prevents inflammatory cell damage, demonstrating therapeutic relevance for clinical conditions such as ulcerative colitis, rheumatoid arthritis, and psoriasis.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.